MedTrace Logo

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults

NCT01160172 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2017-05-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of several formulations of an investigational Staphylococcal vaccine.

Conditions

  • Infections, Staphylococcal

Interventions

BIOLOGICAL

Staphylococcal investigational vaccine GSK2392103A

intramuscular vaccination according to protocol schedule

BIOLOGICAL

Staphylococcal investigational vaccine GSK2392105A

intramuscular vaccination according to protocol schedule

BIOLOGICAL

Staphylococcal investigational vaccine GSK2392106A

intramuscular vaccination according to protocol schedule

BIOLOGICAL

Staphylococcal investigational vaccine GSK2392019A

intramuscular vaccination according to protocol schedule

DRUG

Saline placebo

intramuscular vaccination according to protocol schedule

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-19
Primary Completion
2012-08-23
Completion
2012-08-23

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01160172 on ClinicalTrials.gov